ADVANCED BREAST CANCER

This study tests a new combination of two drugs (saruparib and camizestrant) against standard treatments for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people with inherited BRCA1, BRCA2, or PALB2 mutations. The goal is to see if the new…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This study tests two drugs together for people with advanced breast cancer that cannot be removed by surgery. SYS6023 targets a protein called HER3 on cancer cells, while KN026 targets HER2. The goal is to see if the combination is safe and shrinks tumors. About 36 adults with co…

This study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with ea…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This early-stage trial tests a new drug called MEN2312, alone or with another drug (elacestrant), in 240 adults with advanced breast cancer that has specific genetic changes. The main goals are to find a safe dose and check for side effects. It is the first time MEN2312 is being …

This study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…

This study looks at whether using radiotherapy before immunotherapy can help control advanced breast cancer that has spread or cannot be removed by surgery. About 150 adults who have already had radiotherapy will receive immunotherapy, and researchers will track how long it takes…

This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…

This study tests a drug called trastuzumab deruxtecan (T-DXd) against the usual treatment (a CDK4/6 inhibitor plus hormone therapy) for people with a certain type of advanced breast cancer. The cancer must be hormone receptor-positive, HER2-low or ultralow, and have a specific ge…

This Phase 1 trial is testing ZOLADEX (goserelin), a hormone-blocking implant, in 88 premenopausal women with HR+/HER2- advanced breast cancer. The goal is to see if it can temporarily shut down ovarian function, which may help control the cancer. Participants receive two injecti…

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This trial tests a drug called Disitamab vedotin (RC48-ADC) in 36 people with HER2-low advanced breast cancer that cannot be cured. Participants have had only one prior chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is. This is an early study, so r…

This early-stage study is testing a new oral drug, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Abo…

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This study tests a drug called disitamab vedotin in 100 adults with advanced breast cancer that has spread and is hard to treat. Participants must have tumors with HER2 protein and have had prior treatment. They receive the drug into a vein every two weeks. Researchers will check…

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…

This early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…

This study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to se…

This study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation) live longer without their cancer getting worse. About 240 adults whose cancer has stopped responding to standard hormone thera…

This study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This study is testing a drug called dalpiciclib in people with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the drug can keep the cancer from growing and what side effects it causes. About 103 participants will take dalpicicl…

This early-stage trial is testing a treatment called X-PACT for people with advanced head and neck cancer, breast cancer, soft tissue sarcoma, or melanoma that has not responded to standard treatments. X-PACT involves injecting a drug called methoxsalen directly into the tumor an…

This phase 2 study is testing several drug combinations (fulvestrant plus either neratinib, alpelisib, or everolimus) in 135 postmenopausal women with advanced ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitor treatment. The goal is to see which combination offer…

This phase 2 trial tests a new treatment plan for people with a certain type of advanced breast cancer (HR-positive, HER2-low or ultra-low). Participants first receive trastuzumab rezetecan alone for several months, then switch to a combination of CDK4/6 inhibitors and hormone th…

This Phase 2 trial is testing whether the drug sacituzumab govitecan (Trodelvy) can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received another targeted drug called T-DXd. The study will enroll 75 participan…

This Phase 2 trial tests a drug called patritumab deruxtecan in people with advanced hormone-receptor-positive breast cancer that has stopped responding to hormone therapy and chemotherapy. The drug is designed to seek out and destroy cancer cells that have a protein called HER3 …

This study tests a new way of giving chemotherapy called adaptive therapy for people with advanced breast cancer that has gotten worse after standard treatments. The goal is to see if adjusting the dose over time can help control the cancer longer and with fewer side effects. Abo…

This study tests a treatment called TIL therapy for people with advanced breast cancer who have run out of standard options. Doctors take immune cells from a patient's own tumor, grow them in a lab, and put them back into the body to attack the cancer. The goal is to see if it is…

This study tests whether adding a trastuzumab biosimilar (SB3) to the chemotherapy drug eribulin helps control advanced HER2-positive breast cancer better than eribulin alone. It includes 180 adults whose cancer has spread or cannot be removed and who have already tried at least …

This study is testing a drug called trastuzumab deruxtecan in 118 adults with advanced breast cancer. The goal is to see how long the drug can keep the cancer from growing and what side effects occur. Participants must be in good overall health (ECOG 0-1) and not pregnant or nurs…

This study compares two ways of taking the drug pyrotinib for people with HER2-positive advanced breast cancer: taking it every day (continuous) or taking breaks (intermittent). The goal is to see which schedule works better and has fewer side effects. About 186 adults whose canc…

This study tests a new drug called QL1706 in people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if it can slow down the cancer's growth and check for side effects. About 123 women will take part, and the results will be compared to standard care.

This study tests two experimental drugs, MHB036C and MHB039A, given together to people with advanced breast cancer or other advanced solid tumors that have spread. The goal is to see if the combination is safe and can shrink tumors. About 210 adults aged 18 to 75 with measurable …

This early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants…

This study compares a combination of two chemotherapy pills (capecitabine and cyclophosphamide) against standard maintenance treatments for women with advanced breast cancer whose disease is under control after initial therapy. The goal is to see which approach better delays canc…

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This early-phase study tests a new radioactive imaging agent called [68Ga]Ga-DWJ155 in 36 adults with advanced breast cancer or non-small cell lung cancer. The agent is designed to bind to a target on cancer cells and show up on PET scans, helping doctors see where the cancer has…

This study tests a telehealth program called ENGAGE for people with stage IV breast, prostate, lung, or colorectal cancer. The program helps manage symptoms like pain, fatigue, and distress that interfere with daily life. About 190 participants will be randomly assigned to ENGAGE…

This study tests whether a smartphone app that lets cancer patients report their symptoms, combined with regular calls from a specially trained nurse, can help them better manage chemotherapy side effects and improve their quality of life. The study includes 414 adults with early…

This study explores whether regular video or phone check-ins between hospice patients with advanced breast cancer and their oncology team can improve the hospice experience. About 200 participants, along with their caregivers and nurses, will take part. The goal is to see if this…

This pilot study will test a decision support tool called COAST, available as a booklet and website, designed to help people with stage IV breast cancer have better conversations with their doctors about treatment options. About 100 patients will use the tool and fill out surveys…

This study is following over 6,000 breast cancer patients in Germany to see what treatments they actually receive in routine care and how they fare over time. Researchers are collecting data on treatment patterns, survival, and quality of life from patients with early and advance…

This study looks at how well certain markers in tumors can predict whether a type of targeted cancer treatment called antibody-drug conjugates (ADCs) will work. About 400 adults with advanced breast, stomach, bladder, or lung cancer will provide tumor samples before and after tre…

This study is testing whether a special type of PET-CT scan (F-18 FDG PET-CT) can better track how well treatment is working in people with advanced breast cancer compared to standard imaging like CT scans. Researchers will follow 100 patients for 48 weeks after they start their …